NIAID launched the Antibacterial Resistance Leadership Group (ARLG) in 2013, a major new clinical effort to address antibacterial resistance (AR). The ARLG has developed a clinical research agenda identifying the most pressing clinical questions in AR. Studies conducted by the ARLG may include clinical testing of new drugs to treat multidrug-resistant Gram-negative bacteria, evaluating diagnostic devices in clinical settings, evaluating the effectiveness of new antibacterial stewardship programs, and optimizing treatment regimens to reduce the emergence of resistance. The ARLG is drawing on the creativity of the global research community by inviting concept submissions to identify and address AR priorities. Visit the ARLG website for more information.
Last Updated March 04, 2015